Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $8.20 Consensus Price Target from Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has received a consensus recommendation of “Reduce” from the twelve analysts that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $8.20.

Several research firms recently issued reports on FULC. JPMorgan Chase & Co. lowered shares of Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a research report on Wednesday, June 3rd. Citigroup downgraded shares of Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a report on Tuesday, June 2nd. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price objective on the stock. in a research note on Tuesday, June 2nd. Piper Sandler cut shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a research note on Tuesday, June 2nd. Finally, Leerink Partners lowered shares of Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 price objective for the company. in a report on Tuesday, June 2nd.

Fulcrum Therapeutics Trading Up 4.3%

Shares of Fulcrum Therapeutics stock opened at $3.65 on Monday. Fulcrum Therapeutics has a 1 year low of $2.83 and a 1 year high of $15.74. The company’s fifty day simple moving average is $4.58 and its 200-day simple moving average is $7.42. The company has a market cap of $243.20 million, a price-to-earnings ratio of -3.17 and a beta of 3.01.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.06. As a group, research analysts forecast that Fulcrum Therapeutics will post -0.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Fulcrum Therapeutics news, Director Alan Ezekowitz sold 18,000 shares of Fulcrum Therapeutics stock in a transaction on Friday, June 26th. The stock was sold at an average price of $3.65, for a total value of $65,700.00. Following the completion of the transaction, the director owned 10,927 shares in the company, valued at approximately $39,883.55. The trade was a 62.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Fulcrum Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Boothbay Fund Management LLC increased its position in Fulcrum Therapeutics by 104.2% during the third quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company’s stock worth $6,241,000 after buying an additional 346,136 shares during the last quarter. Braidwell LP acquired a new stake in shares of Fulcrum Therapeutics during the third quarter worth $2,019,000. Aberdeen Group plc raised its position in shares of Fulcrum Therapeutics by 809.0% in the fourth quarter. Aberdeen Group plc now owns 1,254,027 shares of the company’s stock valued at $14,183,000 after buying an additional 1,116,066 shares in the last quarter. Catalio Capital Management LP bought a new stake in shares of Fulcrum Therapeutics in the fourth quarter valued at approximately $2,277,000. Finally, Nicholas Investment Partners LP bought a new stake in shares of Fulcrum Therapeutics in the fourth quarter valued at approximately $2,069,000. Institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.